Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCAP-XX Regulatory News (CPX)

Share Price Information for CAP-XX (CPX)

Share Price is delayed by 15 minutes
Get Live Data
0.265    -0.005 (-1.85%)
Bid:
0.25
Ask:
0.28
Spread: 0.03 (12.00%)
Market Cap: £15.36m
CPX Live PriceLast checked at - London Stock Exchange

Intraday CAP-XX Share Chart

Trading update

20 Jun 2018 07:00

RNS Number : 9258R
CAP-XX Limited
20 June 2018
 

Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR).

 

20 June 2018

 

CAP-XX Limited

("CAP-XX" or "the Company")

Trading update

 

The Board of CAP-XX is pleased to announce that as it approaches the end of its financial year ending 30 June 2018, the Company has received a sharp increase in enquiry levels across all product ranges, including its recently announced 3 Volt technology. Total enquiries, if converted to orders, would amount to annualised sales in excess of US$20m per annum, including over US$2m which has already been classed as design wins, covering over 70 projects for cylindrical and automotive supercapacitors; small IoT and Thinline supercapacitors; and the new 3 Volt prismatic supercapacitors that are in development.

Following on from the announcement made in April 2018, the Company's new 3 Volt technology programme remains on track. As previously stated, the Board believes that the development of a 3 Volt prismatic supercapacitor will be a breakthrough for IoT applications using coin cell batteries. CAP-XX is currently commencing production trials and holding discussions with potential customers and licencees.

Royalty payments continue to grow strongly. Licensing activity remains a key focus, as CAP-XX negotiates new agreements and tackles intellectual property infringements. The Company expects to announce further progress in these respects shortly.

Revenues for the second half of the financial year ending 30 June 2018 are expected to be A$3.35m, including licence payments from AVX, which are significantly ahead of the first half of the year (first half total revenues: A$1.54m). These revenues are expected to result in a reduced EBITDA loss for the second half of the year of approximately A$120,000, compared to the first half EBITDA loss of A$1.5m.

The second half of the financial year includes revenues from the previously announced high volume order for prismatic cells, which has reduced the Company's average selling price by approximately 20%. This selling price reduction, together with the extra start-up costs for this production (as already reported); relocating manufacturing assets from a former contract manufacturer's site; and pursuing patent infringement actions, has reduced the Company's margins. For the financial year ending 30 June 2018, the Board therefore anticipates CAP-XX will generate total revenues of not less than A$4.9m and an EBITDA loss of A$1.6m. Closing cash is anticipated to be in excess of A$1.8m.

 

For further information contact:

 

CAP-XX Limited

Anthony Kongats (Chief Executive Officer) +61 (0) 2 9428 0139

Kreab (Financial PR)

Robert Speed +44 (0) 20 7074 1800

Allenby Capital (Nominated Adviser and Broker)

David Hart / Alex Brearley (Corporate Finance) +44 (0) 20 3328 5656

 

More information is available at www.cap-xx.com

 

Notes to Editors:

CAP-XX (LSE: CPX) is a world leader in the design and manufacture of thin, flat supercapacitors and energy management systems used in portable and small-scale electronic devices, and large supercapacitor based modules used in larger applications such as automotive and renewable energy. The unique feature of CAP-XX supercapacitors is their very high power density and high energy storage capacity in a space-efficient prismatic package. These attributes are essential in power-hungry consumer and industrial electronics, and deliver similar benefits in automotive and other transportation applications. For more information about CAP-XX, visit www.cap-xx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTGGUBPQUPRPPB
Date   Source Headline
31st Oct 20244:35 pmRNSProposed Fundraising
21st Oct 20249:57 amRNSUpdate re. final results and current trading
16th Oct 20247:00 amRNSContract Win
5th Sep 20247:00 amRNSTrading Update and Notice of Results
30th Aug 20245:00 pmRNSTotal Voting Rights
14th Aug 20247:12 amRNSGrant of options
6th Aug 20249:18 amRNSHolding(s) in Company
5th Aug 20247:00 amRNSExercise of warrants and total voting rights
29th Jul 20247:00 amRNSHolding(s) in Company
16th Jul 20247:00 amRNSMOU to establish technology partnership
18th Jun 20247:00 amRNSBoard Changes and Grant of Share Options
20th May 20247:00 amRNSHolding(s) in Company
13th May 20247:00 amRNSHolding(s) in Company
7th May 202410:10 amRNSHolding(s) in Company
7th May 20247:00 amRNSTrading Update
1st May 202411:08 amRNSHolding(s) in Company
30th Apr 20245:00 pmRNSTotal Voting Rights
25th Apr 20249:24 amRNSHolding(s) in Company
24th Apr 20245:04 pmRNSN05/24 - CAP-XX Limited - Restoration of trading
23rd Apr 20248:36 amRNSResult of General Meeting
8th Apr 20249:12 amRNSLitigation with Kyocera AVX settled
28th Mar 20245:00 pmRNSTotal Voting Rights
27th Mar 20248:22 amRNSSuspension of trading
27th Mar 20247:29 amRNSN04/24 - CAP-XX Limited - Suspension of trading
25th Mar 20247:00 amRNSResult of Retail Offer and Total Voting Rights
22nd Mar 20247:00 amRNSResult of Placing and Notice of General Meeting
21st Mar 20244:40 pmRNSREX Retail Offer
21st Mar 20244:35 pmRNSProposed Placing and Subscription to raise £2.0m
21st Mar 20249:00 amRNSLitigation Settlement Agreement with Tesla, Inc
19th Mar 202412:31 pmRNSHolding(s) in Company
18th Mar 20242:56 pmRNSHolding(s) in Company
15th Mar 202412:50 pmRNSHolding(s) in Company
15th Mar 20247:07 amRNSHolding(s) in Company
14th Mar 20247:00 amRNSUpdate on litigation
13th Mar 20247:00 amRNSCorporate Update
12th Mar 20247:00 amRNSRetirement of CFO
28th Feb 20247:00 amRNSUpdate on litigation and trading
19th Feb 20247:00 amRNSCessation of appeals process
1st Feb 20247:00 amRNSInterim Results
29th Jan 20247:00 amRNSUpdate on Patent Infringement
22nd Jan 202412:57 pmRNSChange of Joint Broker
10th Jan 20247:02 amRNSUpdate on IP and appeals process
29th Dec 20231:00 pmRNSTotal Voting Rights
21st Dec 20237:00 amRNSTrading Update
18th Dec 20237:00 amRNSUpdate on Patent Infringement
7th Dec 20237:00 amRNSCAP-XX finalises two new patents
5th Dec 20237:00 amRNSIssue of Shares and Director/PDMR Shareholdings
1st Dec 20237:00 amRNSUpdate re. R&D rebate and other matters
29th Nov 20237:00 amRNSHolding(s) in Company
22nd Nov 202311:29 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.